A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in Patients With Surgically Resectable, ALK, ROS1, or MET-oncogene Positive Non-small Cell Lung Cancer
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Oct 2017
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Oct 2017.
- 18 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Sep 2017.
- 19 Jun 2017 Planned initiation date changed from 1 May 2017 to 1 Jul 2017.